U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891910) titled 'Iopidine to Decrease Intraocular Pressure Rise After Injections' on Sept. 26.
Brief Summary: This is a prospective, randomized, controlled, open-label, single-site investigator-initiated clinical trial. A total of 120 participants will be randomized in a 1:1 ratio either to receive one drop of apraclonidine 1% ophthalmic solution (Iopidine) approximately 20-30 minutes before a clinically indicated intravitreal injection of Eylea HD or Syfovre, or to a control group that will receive no pre-injection study medication.
The intravitreal injection is part of the participant's routine clinical care. The research-specific intervention fo...